These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 15790433

  • 1. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Lee S, Choi EJ, Jin C, Kim DH.
    Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
    [Abstract] [Full Text] [Related]

  • 2. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E, Mills GB, Tsang BK.
    Cancer Res; 2001 Mar 01; 61(5):1862-8. PubMed ID: 11280739
    [Abstract] [Full Text] [Related]

  • 3. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X, Fraser M, Qiu Q, Tsang BK.
    Gynecol Oncol; 2006 Aug 01; 102(2):348-55. PubMed ID: 16545436
    [Abstract] [Full Text] [Related]

  • 4. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
    St-Germain ME, Gagnon V, Mathieu I, Parent S, Asselin E.
    Int J Oncol; 2004 May 01; 24(5):1311-24. PubMed ID: 15067356
    [Abstract] [Full Text] [Related]

  • 5. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
    Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR.
    Cancer Res; 2000 Oct 01; 60(19):5390-4. PubMed ID: 11034077
    [Abstract] [Full Text] [Related]

  • 6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L.
    Leukemia; 2003 Sep 01; 17(9):1794-805. PubMed ID: 12970779
    [Abstract] [Full Text] [Related]

  • 7. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.
    Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR.
    Oncogene; 2005 May 19; 24(22):3574-82. PubMed ID: 15806173
    [Abstract] [Full Text] [Related]

  • 8. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells.
    Lee S, Yoon S, Kim DH.
    Gynecol Oncol; 2007 Feb 19; 104(2):338-44. PubMed ID: 17023032
    [Abstract] [Full Text] [Related]

  • 9. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
    Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W.
    Oncogene; 2003 Sep 18; 22(40):6289-95. PubMed ID: 13679867
    [Abstract] [Full Text] [Related]

  • 10. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
    Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, Chou TC, O-Charoenrat P, Levine AJ, Rao PH, Stoffel A.
    Genes Dev; 2002 Apr 15; 16(8):984-93. PubMed ID: 11959846
    [Abstract] [Full Text] [Related]

  • 11. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells.
    Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G, Bellacosa A, Capitani S, Martelli AM.
    Mol Cancer Res; 2003 Jan 15; 1(3):234-46. PubMed ID: 12556562
    [Abstract] [Full Text] [Related]

  • 12. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance.
    Singh M, Chaudhry P, Fabi F, Asselin E.
    BMC Cancer; 2013 May 10; 13():233. PubMed ID: 23663432
    [Abstract] [Full Text] [Related]

  • 13. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
    Chock KL, Allison JM, Shimizu Y, ElShamy WM.
    Cancer Res; 2010 Nov 01; 70(21):8782-91. PubMed ID: 20940403
    [Abstract] [Full Text] [Related]

  • 14. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C, Ding H, Tian J, Wu L, Wang Y, Xing Y, Chen M.
    Cell Physiol Biochem; 2016 Nov 01; 39(1):242-52. PubMed ID: 27336949
    [Abstract] [Full Text] [Related]

  • 15. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
    Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK.
    Cancer Res; 2003 Nov 01; 63(21):7081-8. PubMed ID: 14612499
    [Abstract] [Full Text] [Related]

  • 16. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
    Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ.
    Oncogene; 2000 May 04; 19(19):2324-30. PubMed ID: 10822383
    [Abstract] [Full Text] [Related]

  • 17. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M, Bai T, Tsang BK.
    Int J Cancer; 2008 Feb 01; 122(3):534-46. PubMed ID: 17918180
    [Abstract] [Full Text] [Related]

  • 18. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
    Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, Gutkind JS, Li W.
    Oncogene; 2002 Aug 08; 21(34):5289-300. PubMed ID: 12149650
    [Abstract] [Full Text] [Related]

  • 19. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.
    Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA.
    Oncogene; 2004 Nov 11; 23(53):8571-80. PubMed ID: 15467756
    [Abstract] [Full Text] [Related]

  • 20. Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line.
    Howells LM, Gallacher-Horley B, Houghton CE, Manson MM, Hudson EA.
    Mol Cancer Ther; 2002 Nov 11; 1(13):1161-72. PubMed ID: 12479697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.